Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: October 2023

SenesTech Inc. (NASDAQ: SNES) Geometrically Increases its Addressable Market with the Addition of Evolve(TM) Soft Bait to its Portfolio

Posted on October 30, 2023 by MissionIR

SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its Evolve(TM) Soft Bait (“Evolve”), a minimum-risk solution in a new form, designed to … Continue reading →

Posted in SenesTech Inc. SNES | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023

Posted on October 30, 2023 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Posted on October 30, 2023 by MissionIR

Amyotrophic lateral sclerosis (“ALS”), or Lou Gehrig’s disease, is a progressive and degenerative neuromuscular disease that destroys nerve cells known as motor neurons, which control voluntary muscle movement (https://ibn.fm/bgJGu). A fatal neurological disorder, ALS lowers the life expectancy of patients … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Posted on October 30, 2023 by MissionIR

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

Posted on October 27, 2023 by MissionIR

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants … Continue reading →

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research

Posted on October 27, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

Posted on October 27, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its lead product candidate, Suramin, in … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

Posted on October 27, 2023 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that brings together pharmaceutical professionals, industry … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), QuantumBasel Announce Two-Year Agreement Extension to Fuel Quantum Commercial Adoption

Posted on October 26, 2023 by MissionIR

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services as well as the world’s first commercial supplier of quantum computers, has extended its relationship with QuantumBasel. In addition, according to the announcement, D-Wave is planning to … Continue reading →

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Clearing Path to Submit NDA for PAX-101

Posted on October 26, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, today announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed positive results of the recent data from its PAX-HAT-301 study of suramin in stage one … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment